Acumen Pharmaceuticals, Inc. (ABOS)

Market Cap	111.15M
Revenue (ttm)	n/a
Net Income (ttm)	-81.67M
Shares Out	60.08M
EPS (ttm)	-1.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	745,754
Open	1.780
Previous Close	1.800
Day's Range	1.750 - 1.860
52-Week Range	1.715 - 5.090
Beta	-0.07
Analysts	Strong Buy
Price Target	9.33 (+404.32%)
Earnings Date	Nov 12, 2024

About ABOS

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 1, 2021
• Employees: 52
• Stock Exchange: NASDAQ
• Ticker Symbol: ABOS
• Website: https://acumenpharm.com

Analyst Forecast

According to 3 analysts, the average rating for ABOS stock is "Strong Buy." The 12-month stock price forecast is $9.33, which is an increase of 404.32% from the latest price.

Price Target

$9.33

(404.32% upside)

Analyst Consensus: Strong Buy